Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1582000 | 0.86 | PRMT6 (0.40) | PRMT6BMPR1BP2RY12ADORA1ADORA3 | |
| SCHEMBL6403280 | 0.78 | KDM4E (0.43) | — | |
| SCHEMBL6396808 | 0.77 | ADORA1 (0.52) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL6396450 | 0.77 | ADORA1 (0.52) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL23069320 | 0.73 | ADORA2A (0.43) | PRMT6ADORA2AADORA2BP2RY12ADORA1 | |
| SCHEMBL29770521 | 0.73 | ADORA2A (0.43) | PRMT6ADORA2AADORA2BP2RY12ADORA1 | |
| SCHEMBL29770515 | 0.71 | ADORA2A (0.43) | PRMT6ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL23069389 | 0.71 | ADORA2A (0.43) | PRMT6ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL6404792 | 0.71 | TYMP (0.53) | PRMT6ADORA2AADORA2BP2RY12ADORA1 | |
| SCHEMBL13615540 | 0.70 | PRMT6 (0.46) | PRMT6ADORA2AADORA2BP2RY12ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | PRMT6 751/4885BMPR1B 3000/4885ADORA2A 287/4885 |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | PRMT6 649/4885BMPR1B 3314/4885ADORA2A 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.